stockrowDexCom, Inc.
DXCM Healthcare Medical Devices
DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.
- Revenue
- +11.2%
- EPS
- 0.00%
- Free cash flow
- −52.9%
- Total debt
- +0.31%
Quarter to September 2026, against a year earlier
Follow DXCM
Alert me
DexCom, Inc. (DXCM) Revenue growth
DexCom, Inc.'s revenue growth over the twelve months to 30 September 2026 was 13.0%, down 2.6 percentage points from fiscal 2025 (15.6%). Over the past ten years it has ranged from 11.3% (fiscal 2024) to 55.1% (fiscal 2015); the current reading is higher than 18% of that period. That is above the Medical Devices industry median of 10.4% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 15.6% | 4.26 |
| FY2024 | 11.3% | (13.15) |
| FY2023 | 24.5% | 5.65 |
| FY2022 | 18.8% | (8.24) |
| FY2021 | 27.1% | (3.46) |
| FY2020 | 30.5% | (12.54) |
| FY2019 | 43.1% | (0.50) |
| FY2018 | 43.6% | 18.25 |
| FY2017 | 25.3% | (17.28) |
| FY2016 | 42.6% | (12.48) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 11.2% | (1.90) |
| Jun 2026 | 13.1% | (1.97) |
| Mar 2026 | 15.1% | 1.93 |
| Dec 2025 | 13.1% | (8.52) |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| GKOS Glaukos Corporation compare | 46.9% |
| EW Edwards Lifesciences Corporation compare | 13.4% |
| DXCM DexCom, Inc. | 13.0% |
| BSX Boston Scientific Corporation compare | 8.87% |
| STE STERIS plc compare | 8.12% |
| PHG Koninklijke Philips N.V. compare | 7.98% |
| ZBH Zimmer Biomet Holdings, Inc. compare | 6.98% |
| GEHC GE HealthCare Technologies Inc. compare | 6.87% |
| SNN Smith & Nephew SNATS, Inc. compare | 4.81% |
| Medical Devices industry median | 10.4% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on DXCM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement